Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$204.00 USD

204.00
4,493,768

+0.45 (0.22%)

Updated Nov 4, 2024 09:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PWV

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More

by Kinjel Shah

FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research site in Indiana.

AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs

by Zacks Equity Research

ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.

AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $195.45, moving -0.7% from the previous trading session.

Kinjel Shah headshot

Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

by Kinjel Shah

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHD

AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V

by Zacks Equity Research

ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met overexpression.

Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), AbbVie (ABBV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal

by Zacks Equity Research

Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.

Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment

by Zacks Equity Research

The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Should You Invest in the Vanguard Health Care ETF (VHT)?

by Zacks Equity Research

Sector ETF report for VHT

AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

The latest trading day saw AbbVie (ABBV) settling at $191.26, representing a -1.16% change from its previous close.

EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer

by Zacks Equity Research

If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.

AbbVie (ABBV) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

AbbVie (ABBV) closed at $193.45 in the latest trading session, marking a -1.16% move from the prior day.

RHHBY or ABBV: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

RHHBY vs. ABBV: Which Stock Is the Better Value Option?

Kinjel Shah headshot

TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?

by Kinjel Shah

Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.

AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

by Zacks Equity Research

With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

by Zacks Equity Research

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The Zacks Analyst Blog Highlights Visa, AbbVie, Anheuser-Busch, Servotronics and United-Guardian

by Zacks Equity Research

Visa, AbbVie, Anheuser-Busch, Servotronics and United-Guardian are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Visa, AbbVie & Anheuser-Busch

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Servotronics, Inc. (SVT) and United-Guardian, Inc. (UG).